



Clinical trial results:

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer

Summary

EudraCT number	2005-005485-37
Trial protocol	FI GB CZ BE IE SK HU ES PT DE IT LT LV BG
Global end of trial date	09 April 2014

Results information

Result version number	v1 (current)
This version publication date	20 June 2016
First version publication date	26 July 2015

Trial information

Trial identification

Sponsor protocol code	20050147
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00286091
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Amgen Inc.
Sponsor organisation address	One Amgen Center Drive, Thousand Oaks, CA, United States, 91320
Public contact	IHQ Medical Info – Clinical Trials, Amgen (EUROPE) GmbH, MedinfoInternational@amgen.com
Scientific contact	IHQ Medical Info – Clinical Trials, Amgen (EUROPE) GmbH, MedinfoInternational@amgen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 April 2014
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	09 April 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to compare the treatment effect of denosumab with placebo on prolonging bone metastasis-free survival in men with hormonerefractory (ie, castrate-resistant) prostate cancer who have no bone metastasis at baseline.

Protection of trial subjects:

This study was conducted in accordance with relevant country regulations and the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines.

Before any subject participated in the study, the investigator obtained written informed consent from the subject following adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study. Informed consent was obtained before any protocol-specific screening procedures were performed or administration of investigational product.

The study protocol, subject information, and informed consent forms were reviewed and approved by the independent ethics committee (IEC) or institutional review board (IRB) for each study center.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 February 2006
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 304
Country: Number of subjects enrolled	Canada: 161
Country: Number of subjects enrolled	France: 135
Country: Number of subjects enrolled	Brazil: 115
Country: Number of subjects enrolled	Czech Republic: 53
Country: Number of subjects enrolled	South Africa: 51
Country: Number of subjects enrolled	Argentina: 50
Country: Number of subjects enrolled	Australia: 45
Country: Number of subjects enrolled	Slovakia: 44
Country: Number of subjects enrolled	Poland: 43
Country: Number of subjects enrolled	Ukraine: 39
Country: Number of subjects enrolled	Mexico: 38
Country: Number of subjects enrolled	Spain: 38
Country: Number of subjects enrolled	New Zealand: 34
Country: Number of subjects enrolled	Finland: 32
Country: Number of subjects enrolled	Russian Federation: 30

Country: Number of subjects enrolled	Netherlands: 29
Country: Number of subjects enrolled	India: 26
Country: Number of subjects enrolled	United Kingdom: 25
Country: Number of subjects enrolled	Serbia: 23
Country: Number of subjects enrolled	Portugal: 22
Country: Number of subjects enrolled	Belgium: 21
Country: Number of subjects enrolled	Bulgaria: 18
Country: Number of subjects enrolled	Germany: 17
Country: Number of subjects enrolled	Italy: 10
Country: Number of subjects enrolled	Hungary: 8
Country: Number of subjects enrolled	Lithuania: 7
Country: Number of subjects enrolled	Ireland: 6
Country: Number of subjects enrolled	Latvia: 6
Country: Number of subjects enrolled	Switzerland: 2
Worldwide total number of subjects	1432
EEA total number of subjects	514

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	234
From 65 to 84 years	1066
85 years and over	132

Subject disposition

Recruitment

Recruitment details:

Eligible subjects were men ≥ 18 years old with histologically-confirmed, castrate-resistant prostate cancer who were chemically or surgically castrated.

The first patient was enrolled into the study on 03 February 2006 and the last patient was enrolled on 23 July 2008.

Pre-assignment

Screening details:

Participants were randomized to denosumab or placebo in the double-blind treatment phase. All participants undergoing scheduled assessments were offered open-label denosumab for up to 3 years in the open-label extension phase. Three enrolled patients were excluded from all datasets per ethics committee's instructions due to eligibility violations.

Period 1

Period 1 title	Double-blind Treatment Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Participants received placebo subcutaneous injection every 4 weeks (Q4W) in the double-blind treatment phase.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subcutaneous injection every 4 weeks (Q4W) in the double-blind treatment phase

Arm title	Denosumab
------------------	-----------

Arm description:

Participants received 120 mg denosumab administered by subcutaneous injection every 4 weeks in the double-blind treatment phase.

Arm type	Experimental
Investigational medicinal product name	Denosumab
Investigational medicinal product code	AMG162
Other name	XGEVA®
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

120 mg denosumab administered by subcutaneous injection every 4 weeks

Number of subjects in period 1	Placebo	Denosumab
Started	716	716
Received Treatment	709	716
On Study at Primary Data Analysis Cutoff	164	174
Completed	132	123
Not completed	584	593
Consent withdrawn by subject	103	113
Protocol-Specified Criteria	307	269
Ineligibility Determined	1	2
Adverse event, non-fatal	28	40
Protocol Deviation	1	3
Other	25	33
Death	58	65
Administrative Decision	20	21
Lost to follow-up	11	4
Disease Progression	22	35
Noncompliance	8	8

Period 2

Period 2 title	Open-label Treatment Phase
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo/Denosumab

Arm description:

Participants who received placebo in the double-blind treatment phase then received open-label denosumab 120 mg by subcutaneous injection once every 4 weeks for up to 3 years in the open-label extension phase.

Arm type	Experimental
Investigational medicinal product name	Denosumab
Investigational medicinal product code	AMG162
Other name	XGEVA®
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

120 mg denosumab administered by subcutaneous injection every 4 weeks

Arm title	Denosumab/Denosumab
-----------	---------------------

Arm description:

Participants who received denosumab in the double-blind treatment phase then received open-label

denosumab 120 mg by subcutaneous injection once every 4 weeks for up to 3 years in the open-label extension phase.

Arm type	Experimental
Investigational medicinal product name	Denosumab
Investigational medicinal product code	AMG162
Other name	XGEVA®
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

120 mg denosumab administered by subcutaneous injection every 4 weeks

Number of subjects in period 2^[1]	Placebo/Denosumab	Denosumab/Denosumab
Started	110	104
Received Treatment	109	101
Completed	33	33
Not completed	77	71
Physician decision	24	21
Consent withdrawn by subject	14	10
Protocol-Specified Criteria	1	-
Missing End of Study Information	-	1
Adverse event, non-fatal	5	16
Other	11	11
Death	10	7
Lost to follow-up	-	1
Disease Progression	9	3
Noncompliance	3	1

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Participants in the Czech Republic and United Kingdom were enrolled under a separate protocol for the open-label phase phase per Health Authority request, and are reported separately (Study 20080585; 2010-021846-23).

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description:	
Participants received placebo subcutaneous injection every 4 weeks (Q4W) in the double-blind treatment phase.	
Reporting group title	Denosumab
Reporting group description:	
Participants received 120 mg denosumab administered by subcutaneous injection every 4 weeks in the double-blind treatment phase.	

Reporting group values	Placebo	Denosumab	Total
Number of subjects	716	716	1432
Age categorical			
Units: Subjects			

Age Continuous			
Units: years			
arithmetic mean	73.2	73.2	
standard deviation	± 8.3	± 8.8	-
Gender, Male/Female			
Units: participants			
Female	0	0	0
Male	716	716	1432
Race/Ethnicity, Customized			
Units: Subjects			
White or Caucasian	604	606	1210
Black or African American	35	41	76
Hispanic or Latino	37	32	69
Asian	18	17	35
Japanese	2	0	2
American Indian or Alaska Native	2	0	2
Native Hawaiian or Other Pacific Islander	1	0	1
Other	17	18	35
Unknown	0	2	2
Eastern Cooperative Oncology Group (ECOG) performance Status			
A scale to assess a patient's disease status. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; 2 = Ambulatory and capable of all self care, unable to carry out any work activities. Up and about > 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair > 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.			
Units: Subjects			
Grade 0	514	505	1019
Grade 1	199	210	409
Grade 2	3	1	4
Grade 3	0	0	0
Grade 4	0	0	0
Prostate-Specific Antigen (PSA)			

Doubling Time			
Units: Subjects			
≤ 10 months	580	574	1154
> 10 months	136	142	278
Prostate-Specific Antigen (PSA) ≥ 8.0 ng/mL			
Units: Subjects			
Yes	471	473	944
No	245	243	488
Prior Chemotherapy Regimens			
Units: Subjects			
Yes	54	63	117
No	662	653	1315

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description: Participants received placebo subcutaneous injection every 4 weeks (Q4W) in the double-blind treatment phase.	
Reporting group title	Denosumab
Reporting group description: Participants received 120 mg denosumab administered by subcutaneous injection every 4 weeks in the double-blind treatment phase.	
Reporting group title	Placebo/Denosumab
Reporting group description: Participants who received placebo in the double-blind treatment phase then received open-label denosumab 120 mg by subcutaneous injection once every 4 weeks for up to 3 years in the open-label extension phase.	
Reporting group title	Denosumab/Denosumab
Reporting group description: Participants who received denosumab in the double-blind treatment phase then received open-label denosumab 120 mg by subcutaneous injection once every 4 weeks for up to 3 years in the open-label extension phase.	

Primary: Bone Metastasis-free Survival

End point title	Bone Metastasis-free Survival
End point description: The time to the first occurrence of bone metastasis (either symptomatic or asymptomatic) or death from any cause. Participants who did not experience bone metastasis or on-study death were censored at the last on-study contact date or the primary analysis data cutoff date, whichever came first. Median bone metastasis-free survival time was estimated using the Kaplan-Meier method.	
End point type	Primary
End point timeframe: From the first dose of investigational product to the primary data cutoff date of 30 July 2010; median time on study was approximately 20 months.	

End point values	Placebo	Denosumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	716	716		
Units: days				
median (confidence interval 95%)	768 (675 to 897)	897 (773 to 1014)		

Statistical analyses

Statistical analysis title	Analysis of Bone Metastasis-free Survival
Statistical analysis description: Hazard ratio based on the Cox proportional hazards model stratified by PSA \geq 8.0 ng/mL, PSA doubling	

time \leq 10 months and previous or current chemotherapy for prostate cancer. A hazard ratio < 1 favors denosumab.

Comparison groups	Placebo v Denosumab
Number of subjects included in analysis	1432
Analysis specification	Pre-specified
Analysis type	superiority ^[1]
P-value	= 0.0284
Method	Wald test
Parameter estimate	Hazard ratio (HR)
Point estimate	0.85
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	0.98

Notes:

[1] - Primary and secondary endpoint analyses were conducted hierarchically. To preserve an overall type I error rate of 0.05, a 0.0488 2-sided test of bone metastasis-free survival was performed. If superiority of denosumab over placebo was established, time to first bone metastasis was tested with a 2-sided significance level of 0.050. If superiority of denosumab over placebo was also established, overall survival time was tested at a 2-sided significance level of 0.050.

Secondary: Time to First Bone Metastasis

End point title	Time to First Bone Metastasis
End point description:	Time from randomization to the date of first occurrence of bone metastasis (either symptomatic or asymptomatic), excluding death. Participants who did not develop bone metastasis were censored at their last on-study bone assessment date or the primary analysis data cut-off date, whichever was first. Median time to first bone metastasis was estimated using the Kaplan-Meier method.
End point type	Secondary
End point timeframe:	From the first dose of investigational product to the primary data cutoff date of 30 July 2010; median time on study was approximately 20 months.

End point values	Placebo	Denosumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	716	716		
Units: days				
median (confidence interval 95%)	897 (683 to 1009)	1010 (897 to 1156)		

Statistical analyses

Statistical analysis title	Analysis of Time to First Bone Metastasis
Statistical analysis description:	Hazard ratio based on the Cox proportional hazards model stratified by PSA \geq 8.0 ng/mL, PSA doubling time \leq 10 months and previous or current chemotherapy for prostate cancer. A hazard ratio < 1 favors denosumab.
Comparison groups	Placebo v Denosumab

Number of subjects included in analysis	1432
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0317
Method	Wald test
Parameter estimate	Hazard ratio (HR)
Point estimate	0.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.71
upper limit	0.98

Secondary: Overall Survival

End point title	Overall Survival
End point description:	
Time from randomization to the date of death. Participants who were still alive or lost to follow-up by the primary analysis data cut-off date were censored at their last contact date (on-study or during survival follow-up) or the primary analysis data cut-off date, whichever was first. "99999" indicates values that could not be estimated due to the low number of events at the time of data cut-off.	
End point type	Secondary
End point timeframe:	
From the first dose of investigational product to the primary data cutoff date of 30 July 2010; median time on study was approximately 20 months.	

End point values	Placebo	Denosumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	716	716		
Units: days				
median (confidence interval 95%)	1365 (1220 to 99999)	1335 (1221 to 99999)		

Statistical analyses

Statistical analysis title	Analysis of Overall Survival
Statistical analysis description:	
Hazard ratio based on the Cox proportional hazards model stratified by PSA \geq 8.0 ng/mL, PSA doubling time \leq 10 months and previous or current chemotherapy for prostate cancer. A hazard ratio < 1 favors denosumab.	
Comparison groups	Placebo v Denosumab

Number of subjects included in analysis	1432
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9125
Method	Wald test
Parameter estimate	Hazard ratio (HR)
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.85
upper limit	1.2

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Median investigational product exposure was 18.4 and 19.3 months in the placebo and denosumab groups respectively during the double blind phase and 23.7 and 24.9 months during the open-label treatment phase.

Adverse event reporting additional description:

Four participants who were randomized to placebo received ≥ 1 dose of denosumab; therefore, these participants were included within the denosumab group for the safety analyses.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.0
--------------------	------

Reporting groups

Reporting group title	DB: Placebo
-----------------------	-------------

Reporting group description:

Participants received placebo subcutaneous injection every 4 weeks (Q4W) in the double-blind (DB) treatment phase.

Reporting group title	DB: Denosumab
-----------------------	---------------

Reporting group description:

Participants received 120 mg denosumab administered by subcutaneous injection every 4 weeks in the double-blind treatment phase.

Reporting group title	OLE: Placebo/ Denosumab
-----------------------	-------------------------

Reporting group description:

Participants who received placebo in the double-blind treatment phase received open-label denosumab 120 mg by subcutaneous injection once every 4 weeks for up to 3 years in the open-label extension (OLE) phase.

Reporting group title	OLE: Denosumab/ Denosumab
-----------------------	---------------------------

Reporting group description:

Participants who received denosumab in the double-blind treatment phase received open-label denosumab 120 mg by subcutaneous injection once every 4 weeks for up to 3 years in the open-label extension phase.

Serious adverse events	DB: Placebo	DB: Denosumab	OLE: Placebo/ Denosumab
Total subjects affected by serious adverse events			
subjects affected / exposed	332 / 705 (47.09%)	341 / 720 (47.36%)	39 / 109 (35.78%)
number of deaths (all causes)	326	352	23
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	2 / 705 (0.28%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder cancer			
subjects affected / exposed	2 / 705 (0.28%)	7 / 720 (0.97%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 8	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder cancer recurrent			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Choroid melanoma			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer metastatic			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Colorectal cancer			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric cancer			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stromal tumour			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal tract adenoma			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine benign neoplasm			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal cancer			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lip squamous cell carcinoma			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipoma			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mantle cell lymphoma			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningioma			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to abdominal cavity			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Metastases to bladder			
subjects affected / exposed	2 / 705 (0.28%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Metastases to bone			
subjects affected / exposed	5 / 705 (0.71%)	10 / 720 (1.39%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 10	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 3	0 / 0
Metastases to central nervous system			
subjects affected / exposed	2 / 705 (0.28%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Metastases to larynx			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to liver			
subjects affected / exposed	4 / 705 (0.57%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 0
Metastases to lung			

subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to lymph nodes			
subjects affected / exposed	6 / 705 (0.85%)	6 / 720 (0.83%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 3	0 / 0
Metastases to peritoneum			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to skin			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to small intestine			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to soft tissue			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to spine			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastasis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Metastatic malignant melanoma			

subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic pain			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic squamous cell carcinoma			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myeloproliferative disorder			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasm prostate			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-Hodgkin's lymphoma			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-small cell lung cancer			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal adenocarcinoma			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal carcinoma			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatic carcinoma			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pancreatic neoplasm			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Papillary thyroid cancer			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papilloma			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	21 / 705 (2.98%)	15 / 720 (2.08%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 27	0 / 16	0 / 1
deaths causally related to treatment / all	0 / 11	0 / 8	0 / 0
Prostate cancer metastatic			
subjects affected / exposed	6 / 705 (0.85%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 6	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
Prostate cancer recurrent			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal adenocarcinoma			
subjects affected / exposed	2 / 705 (0.28%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Rectal cancer			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectosigmoid cancer			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cancer			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cell carcinoma			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small cell lung cancer			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestine carcinoma			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic dilatation			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arterial thrombosis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	6 / 705 (0.85%)	8 / 720 (1.11%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 6	2 / 8	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage			

subjects affected / exposed	0 / 705 (0.00%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	3 / 705 (0.43%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	4 / 705 (0.57%)	5 / 720 (0.69%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intermittent claudication			
subjects affected / exposed	1 / 705 (0.14%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoedema			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic venous thrombosis			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebitis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis			
subjects affected / exposed	3 / 705 (0.43%)	1 / 720 (0.14%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Vascular occlusion			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasculitis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis limb			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Bladder catheterisation			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cancer surgery			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardioversion			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract operation			
subjects affected / exposed	2 / 705 (0.28%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colostomy			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystostomy			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Debridement			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Finger amputation			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heart valve operation			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip arthroplasty			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia repair			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Knee arthroplasty			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orchidectomy			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin graft			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stent placement			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transurethral prostatectomy			
subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	10 / 705 (1.42%)	9 / 720 (1.25%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 10	0 / 10	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	3 / 705 (0.43%)	4 / 720 (0.56%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	4 / 705 (0.57%)	4 / 720 (0.56%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 4	0 / 4	0 / 1
Device battery issue			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device malfunction			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device occlusion			
subjects affected / exposed	1 / 705 (0.14%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Fatigue			
subjects affected / exposed	0 / 705 (0.00%)	3 / 720 (0.42%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 3	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	3 / 705 (0.43%)	5 / 720 (0.69%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Generalised oedema			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hernia			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Impaired healing			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Local swelling			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 705 (0.00%)	6 / 720 (0.83%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Multi-organ failure			
subjects affected / exposed	2 / 705 (0.28%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 2	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	2 / 705 (0.28%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pain			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	5 / 705 (0.71%)	10 / 720 (1.39%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 15	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden cardiac death			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Physical disability			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	3 / 705 (0.43%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic pain			
subjects affected / exposed	2 / 705 (0.28%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perineal pain			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatic haemorrhage			
subjects affected / exposed	3 / 705 (0.43%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Prostatic obstruction			
subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	4 / 109 (3.67%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatic perforation			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatism			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatomegaly			
subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scrotal oedema			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular atrophy			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular pain			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0

Acute respiratory distress syndrome			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspiration			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchomalacia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	3 / 705 (0.43%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cough			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			

subjects affected / exposed	7 / 705 (0.99%)	10 / 720 (1.39%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 8	0 / 11	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Emphysema			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung disorder			
subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	5 / 705 (0.71%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleuritic pain			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary arterial hypertension			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	8 / 705 (1.13%)	9 / 720 (1.25%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	1 / 8	2 / 9	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 2	0 / 0
Pulmonary fibrosis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	3 / 705 (0.43%)	3 / 720 (0.42%)	2 / 109 (1.83%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 3	0 / 0	0 / 1
Sinus disorder			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Abnormal behaviour			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Completed suicide			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Confusional state			
subjects affected / exposed	4 / 705 (0.57%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disorientation			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			

subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Aspiration bronchial			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood potassium decreased			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood pressure increased			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood urine present			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoglobin decreased			
subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heart rate increased			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laboratory test abnormal			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ultrasound liver abnormal			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight decreased			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back injury			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical vertebral fracture			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis radiation			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial bones fracture			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			

subjects affected / exposed	1 / 705 (0.14%)	6 / 720 (0.83%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	1 / 705 (0.14%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	8 / 705 (1.13%)	1 / 720 (0.14%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 8	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibula fracture			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foreign body			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis radiation			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal stoma complication			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			

subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	2 / 705 (0.28%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laceration			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			
subjects affected / exposed	2 / 705 (0.28%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematuria			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal injury			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sternal fracture			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	2 / 705 (0.28%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	3 / 705 (0.43%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	3 / 705 (0.43%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic intracranial haemorrhage			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Wrist fracture			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Phimosis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syringomyelia			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0

Acute myocardial infarction			
subjects affected / exposed	2 / 705 (0.28%)	4 / 720 (0.56%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Angina pectoris			
subjects affected / exposed	3 / 705 (0.43%)	5 / 720 (0.69%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	4 / 705 (0.57%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	12 / 705 (1.70%)	6 / 720 (0.83%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 14	2 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial tachycardia			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	2 / 705 (0.28%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			

subjects affected / exposed	3 / 705 (0.43%)	2 / 720 (0.28%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 1
Cardiac failure			
subjects affected / exposed	3 / 705 (0.43%)	3 / 720 (0.42%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 3	0 / 1
Cardiac failure congestive			
subjects affected / exposed	7 / 705 (0.99%)	6 / 720 (0.83%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 7	1 / 6	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac valve disease			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardio-respiratory arrest			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardiogenic shock			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiomyopathy			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiopulmonary failure			

subjects affected / exposed	0 / 705 (0.00%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 3	0 / 0
Cardiovascular insufficiency			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cor pulmonale			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	3 / 705 (0.43%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery stenosis			
subjects affected / exposed	3 / 705 (0.43%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery thrombosis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Ischaemic cardiomyopathy			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction			
subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			

subjects affected / exposed	10 / 705 (1.42%)	12 / 720 (1.67%)	4 / 109 (3.67%)
occurrences causally related to treatment / all	1 / 10	0 / 12	0 / 4
deaths causally related to treatment / all	0 / 3	0 / 6	0 / 1
Myocardial ischaemia			
subjects affected / exposed	0 / 705 (0.00%)	6 / 720 (0.83%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Right ventricular failure			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sick sinus syndrome			
subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus bradycardia			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Trifascicular block			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular hypertrophy			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachycardia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ataxia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery stenosis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery thrombosis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebellar infarction			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral ischaemia			

subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	10 / 705 (1.42%)	8 / 720 (1.11%)	2 / 109 (1.83%)
occurrences causally related to treatment / all	1 / 13	0 / 8	0 / 2
deaths causally related to treatment / all	1 / 2	0 / 3	0 / 1
Cerebrovascular disorder			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complex partial seizures			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Convulsion			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dementia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 705 (0.00%)	4 / 720 (0.56%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	3 / 705 (0.43%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait apraxia			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Grand mal convulsion			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiparesis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertonia			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lethargy			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathy peripheral			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraparesis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parkinson's disease			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Petit mal epilepsy			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	4 / 705 (0.57%)	8 / 720 (1.11%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	1 / 6	1 / 9	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vertebral artery occlusion			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	12 / 705 (1.70%)	25 / 720 (3.47%)	2 / 109 (1.83%)
occurrences causally related to treatment / all	0 / 15	2 / 30	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Anaemia of malignant disease			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone marrow failure			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulopathy			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	1 / 705 (0.14%)	4 / 720 (0.56%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic anaemia			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency anaemia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal lymphadenopathy			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spontaneous haematoma			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			

Cataract			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eyelid ptosis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glaucoma			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Optic ischaemic neuropathy			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	6 / 705 (0.85%)	3 / 720 (0.42%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	1 / 6	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain lower			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute abdomen			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal haemorrhage			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ascites			
subjects affected / exposed	3 / 705 (0.43%)	2 / 720 (0.28%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Colitis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	2 / 705 (0.28%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 705 (0.14%)	4 / 720 (0.56%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis intestinal haemorrhagic			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal haemorrhagic			

subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal ulcer			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspepsia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterovesical fistula			
subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer			
subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal angiodysplasia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorder			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	2 / 705 (0.28%)	5 / 720 (0.69%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematemesis			
subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematochezia			
subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus paralytic			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	3 / 705 (0.43%)	4 / 720 (0.56%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia, obstructive			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal haemorrhage			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal mass			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	4 / 705 (0.57%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-abdominal haemorrhage			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Large intestinal stenosis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			

subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine polyp			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	3 / 705 (0.43%)	1 / 720 (0.14%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal rupture			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal stenosis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral mucosa erosion			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peptic ulcer perforation			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periodontal disease			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	4 / 705 (0.57%)	6 / 720 (0.83%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 8	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal stenosis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal haemorrhage			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	3 / 705 (0.43%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Subileus			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tongue haemorrhage			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toothache			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varices oesophageal			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	3 / 705 (0.43%)	1 / 720 (0.14%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Bile duct stone			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	3 / 705 (0.43%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholestasis			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaundice			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis contact			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin ulcer			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Anuria			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Azotaemia			
subjects affected / exposed	0 / 705 (0.00%)	5 / 720 (0.69%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder dilatation			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder neck obstruction			
subjects affected / exposed	1 / 705 (0.14%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder neck sclerosis			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder obstruction			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder outlet obstruction			
subjects affected / exposed	2 / 705 (0.28%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder perforation			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus bladder			
subjects affected / exposed	3 / 705 (0.43%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus ureteric			
subjects affected / exposed	0 / 705 (0.00%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis haemorrhagic			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis noninfective			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysuria			
subjects affected / exposed	3 / 705 (0.43%)	7 / 720 (0.97%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 8	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	25 / 705 (3.55%)	37 / 720 (5.14%)	2 / 109 (1.83%)
occurrences causally related to treatment / all	0 / 36	1 / 45	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage urinary tract			
subjects affected / exposed	2 / 705 (0.28%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	11 / 705 (1.56%)	15 / 720 (2.08%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 11	0 / 18	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Hydroureter			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incontinence			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Micturition disorder			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Micturition urgency			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nocturia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive uropathy			
subjects affected / exposed	2 / 705 (0.28%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Oliguria			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pollakiuria			
subjects affected / exposed	1 / 705 (0.14%)	6 / 720 (0.83%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyuria			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			

subjects affected / exposed	9 / 705 (1.28%)	16 / 720 (2.22%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 11	0 / 17	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 6	0 / 0
Renal failure acute			
subjects affected / exposed	16 / 705 (2.27%)	12 / 720 (1.67%)	4 / 109 (3.67%)
occurrences causally related to treatment / all	0 / 17	0 / 14	0 / 4
deaths causally related to treatment / all	0 / 3	0 / 2	0 / 1
Renal failure chronic			
subjects affected / exposed	3 / 705 (0.43%)	2 / 720 (0.28%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric dilatation			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric obstruction			
subjects affected / exposed	4 / 705 (0.57%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Ureteric stenosis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral obstruction			
subjects affected / exposed	3 / 705 (0.43%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral pain			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral stenosis			

subjects affected / exposed	4 / 705 (0.57%)	3 / 720 (0.42%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 4	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary bladder haemorrhage			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary hesitation			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary incontinence			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	33 / 705 (4.68%)	56 / 720 (7.78%)	6 / 109 (5.50%)
occurrences causally related to treatment / all	0 / 40	0 / 68	0 / 7
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Urinary tract disorder			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	12 / 705 (1.70%)	5 / 720 (0.69%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 12	1 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract pain			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urine abnormality			

subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urogenital haemorrhage			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 705 (0.28%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	7 / 705 (0.99%)	9 / 720 (1.25%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	1 / 7	0 / 9	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dupuytren's contracture			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Exostosis of jaw			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flank pain			

subjects affected / exposed	2 / 705 (0.28%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fracture nonunion			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercreatinaemia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc degeneration			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc disorder			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Jaw disorder			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint effusion			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			

subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteitis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	4 / 705 (0.57%)	7 / 720 (0.97%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 4	1 / 8	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis of jaw			
subjects affected / exposed	0 / 705 (0.00%)	12 / 720 (1.67%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	13 / 13	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			

subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatoid arthritis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal osteoarthritis			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight bearing difficulty			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess jaw			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess of salivary gland			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute sinusitis			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal infection			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis bacterial			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	4 / 705 (0.57%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			

subjects affected / exposed	0 / 705 (0.00%)	3 / 720 (0.42%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac infection			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cellulitis			
subjects affected / exposed	4 / 705 (0.57%)	6 / 720 (0.83%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 4	0 / 6	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest wall abscess			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic sinusitis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium bacteraemia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium colitis			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dental fistula			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related sepsis			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	1 / 705 (0.14%)	2 / 720 (0.28%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Empyema			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterococcal infection			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epiglottitis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gangrene			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	2 / 705 (0.28%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal infection			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gingival abscess			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Human ehrlichiosis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected skin ulcer			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver abscess			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lobar pneumonia			

subjects affected / exposed	2 / 705 (0.28%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	0 / 705 (0.00%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Neutropenic infection			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral candidiasis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orchitis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 705 (0.00%)	4 / 720 (0.56%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	1 / 6	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis acute			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis chronic			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Penile infection			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perineal abscess			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perineal infection			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	16 / 705 (2.27%)	13 / 720 (1.81%)	2 / 109 (1.83%)
occurrences causally related to treatment / all	0 / 16	1 / 14	0 / 3
deaths causally related to treatment / all	0 / 5	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonal sepsis			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary tuberculosis			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	2 / 705 (0.28%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scrotal abscess			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	8 / 705 (1.13%)	6 / 720 (0.83%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 8	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 3	0 / 4	0 / 0
Septic shock			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	2 / 109 (1.83%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 2
Sialoadenitis			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth infection			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			

subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	15 / 705 (2.13%)	15 / 720 (2.08%)	2 / 109 (1.83%)
occurrences causally related to treatment / all	0 / 15	0 / 19	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	4 / 705 (0.57%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Viral infection			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	3 / 705 (0.43%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Decreased appetite			
subjects affected / exposed	2 / 705 (0.28%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			

subjects affected / exposed	9 / 705 (1.28%)	7 / 720 (0.97%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 11	0 / 7	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus inadequate control			
subjects affected / exposed	2 / 705 (0.28%)	2 / 720 (0.28%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			
subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypocalcaemia			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	2 / 109 (1.83%)
occurrences causally related to treatment / all	0 / 1	0 / 1	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	1 / 705 (0.14%)	3 / 720 (0.42%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			

subjects affected / exposed	0 / 705 (0.00%)	1 / 720 (0.14%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemia			
subjects affected / exposed	0 / 705 (0.00%)	0 / 720 (0.00%)	1 / 109 (0.92%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iron deficiency			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			
subjects affected / exposed	1 / 705 (0.14%)	1 / 720 (0.14%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 705 (0.14%)	0 / 720 (0.00%)	0 / 109 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	OLE: Denosumab/ Denosumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	36 / 101 (35.64%)		
number of deaths (all causes)	15		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Basal cell carcinoma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Bladder cancer				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bladder cancer recurrent				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Choroid melanoma				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Colon cancer				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colon cancer metastatic				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colorectal cancer				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastric cancer				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal stromal tumour				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal tract adenoma				

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Large intestine benign neoplasm				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Laryngeal cancer				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lip squamous cell carcinoma				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lipoma				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung neoplasm malignant				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Malignant melanoma				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mantle cell lymphoma				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Meningioma				

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to abdominal cavity				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to bladder				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to bone				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to central nervous system				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to larynx				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to liver				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to lung				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to lymph nodes				

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to peritoneum			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to skin			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to small intestine			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to soft tissue			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to spine			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastasis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastatic malignant melanoma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastatic pain			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastatic squamous cell carcinoma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myeloproliferative disorder			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neoplasm prostate			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Non-Hodgkin's lymphoma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Non-small cell lung cancer			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal adenocarcinoma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oesophageal carcinoma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic carcinoma			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatic neoplasm			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Papillary thyroid cancer			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Papilloma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Plasma cell myeloma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prostate cancer			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Prostate cancer metastatic			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prostate cancer recurrent			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal adenocarcinoma			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal cancer			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectosigmoid cancer			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal cancer			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal cell carcinoma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small cell lung cancer			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small intestine carcinoma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tumour haemorrhage			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Aortic aneurysm			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aortic dilatation			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arterial thrombosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Deep vein thrombosis			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Embolism			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematoma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertension			

subjects affected / exposed	3 / 101 (2.97%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Hypertensive crisis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intermittent claudication			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischaemia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphoedema			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Orthostatic hypotension			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pelvic venous thrombosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral arterial occlusive disease			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral ischaemia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Phlebitis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Shock			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Superior vena cava syndrome			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombophlebitis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular occlusion			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vasculitis			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Venous thrombosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Venous thrombosis limb			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Bladder catheterisation			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cancer surgery			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardioversion			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cataract operation			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colostomy			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cystostomy			

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Debridement				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Finger amputation				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Heart valve operation				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hip arthroplasty				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Inguinal hernia repair				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Knee arthroplasty				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Orchidectomy				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Skin graft				

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stent placement			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transurethral prostatectomy			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest pain			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chills			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Death			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Device battery issue			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device malfunction			

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Device occlusion				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Disease progression				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fatigue				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
General physical health deterioration				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Generalised oedema				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hernia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Impaired healing				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Local swelling				

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malaise			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multi-organ failure			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Non-cardiac chest pain			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Oedema peripheral			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sudden cardiac death			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sudden death			

subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Social circumstances			
Physical disability			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pelvic pain			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Perineal pain			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prostatic haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prostatic obstruction			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Prostatic perforation			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prostatism			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prostatomegaly			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Scrotal oedema			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Testicular atrophy			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Testicular pain			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Acute pulmonary oedema			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Acute respiratory failure				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Aspiration				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Asthma				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atelectasis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchomalacia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chronic obstructive pulmonary disease				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cough				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dyspnoea				
subjects affected / exposed	3 / 101 (2.97%)			
occurrences causally related to treatment / all	0 / 5			
deaths causally related to treatment / all	0 / 0			
Emphysema				

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Epistaxis				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Haemoptysis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung disorder				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pleural effusion				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pleuritic pain				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia aspiration				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Pneumonitis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumothorax				

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary arterial hypertension			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	3 / 101 (2.97%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Pulmonary fibrosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary oedema			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory distress			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinus disorder			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sleep apnoea syndrome			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Abnormal behaviour			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Completed suicide			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Confusional state			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Delirium			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Depression			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Disorientation			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mental status changes			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			

Aspiration bronchial				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood creatinine increased				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood potassium decreased				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood pressure increased				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood urine present				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemoglobin decreased				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Heart rate increased				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Laboratory test abnormal				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ultrasound liver abnormal				

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Weight decreased			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Back injury			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cervical vertebral fracture			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cystitis radiation			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Facial bones fracture			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fall			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Femoral neck fracture			

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Femur fracture				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Fibula fracture				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Foreign body				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fracture				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis radiation				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal stoma complication				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Head injury				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hip fracture				

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Humerus fracture				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Incisional hernia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Injury				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Laceration				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lumbar vertebral fracture				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post procedural haematuria				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post procedural haemorrhage				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Radius fracture				

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal injury			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rib fracture			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Road traffic accident			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal compression fracture			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sternal fracture			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subdural haematoma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tendon rupture			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tibia fracture			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Toxicity to various agents			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Traumatic intracranial haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wrist fracture			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Congenital, familial and genetic disorders			
Phimosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syringomyelia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute myocardial infarction			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Angina pectoris				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Angina unstable				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Arrhythmia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrial fibrillation				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Atrial flutter				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrial tachycardia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bradycardia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac arrest				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Cardiac failure				

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac failure congestive			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac tamponade			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac valve disease			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardio-respiratory arrest			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiogenic shock			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiomyopathy			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiopulmonary failure			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiovascular insufficiency			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cor pulmonale			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery disease			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery stenosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery thrombosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischaemic cardiomyopathy			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Left ventricular dysfunction			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Myocardial ischaemia			

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pericardial effusion				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Right ventricular failure				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sick sinus syndrome				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sinus bradycardia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tachycardia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Trifascicular block				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ventricular hypertrophy				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ventricular tachycardia				

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ataxia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carotid artery stenosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Carotid artery thrombosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebellar infarction			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebral infarction			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebral ischaemia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular accident			

subjects affected / exposed	2 / 101 (1.98%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular disorder			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Complex partial seizures			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Convulsion			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dementia			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dizziness			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Encephalopathy			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Epilepsy			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gait apraxia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Grand mal convulsion			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hemiparesis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertonia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischaemic stroke			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lethargy			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Loss of consciousness			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neuropathy peripheral			

subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Paraparesis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Parkinson's disease			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Petit mal epilepsy			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Presyncope			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Somnolence			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal cord compression			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transient ischaemic attack			

subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vertebral artery occlusion			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 101 (2.97%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Anaemia of malignant disease			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bone marrow failure			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coagulopathy			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile neutropenia			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haemorrhagic anaemia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Iron deficiency anaemia			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lymphadenopathy			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retroperitoneal lymphadenopathy			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spontaneous haematoma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Cataract			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eyelid ptosis			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Glaucoma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Optic ischaemic neuropathy			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Abdominal pain lower			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute abdomen			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal fistula			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ascites			

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colitis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colitis ulcerative				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Constipation				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diarrhoea				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis intestinal haemorrhagic				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Diverticulum intestinal				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulum intestinal haemorrhagic				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Duodenal ulcer				

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dyspepsia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enterovesical fistula			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Faecaloma			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastric ulcer			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastritis			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal angiodysplasia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorder			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal haemorrhage			

subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematemesis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematochezia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhoids			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ileus			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ileus paralytic			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia, obstructive			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal mass			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal obstruction			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intra-abdominal haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Large intestinal stenosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Large intestine perforation			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Large intestine polyp			

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lower gastrointestinal haemorrhage				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Melaena				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nausea				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal rupture				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal stenosis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophagitis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oral mucosa erosion				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatitis				

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peptic ulcer perforation			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Periodontal disease			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal stenosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small intestinal haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small intestinal obstruction			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Subileus			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tongue haemorrhage			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Toothache			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Varices oesophageal			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bile duct stone			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholangitis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis acute			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholestasis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic failure			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatitis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperbilirubinaemia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Jaundice			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Angioedema			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dermatitis contact			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin ulcer			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Anuria			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Azotaemia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder dilatation			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder neck obstruction			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder neck sclerosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder obstruction			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder outlet obstruction			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bladder perforation			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Calculus bladder			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Calculus ureteric			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Calculus urinary			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cystitis haemorrhagic			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cystitis noninfective			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dysuria			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	5 / 101 (4.95%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Haemorrhage urinary tract			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hydronephrosis			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hydroureter			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Incontinence			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Micturition disorder			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Micturition urgency			

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nephrolithiasis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nocturia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Obstructive uropathy				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oliguria				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pollakiuria				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Polyuria				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal failure				
subjects affected / exposed	2 / 101 (1.98%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Renal failure acute				

subjects affected / exposed	2 / 101 (1.98%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Renal failure chronic			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ureteric dilatation			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ureteric obstruction			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ureteric stenosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urethral obstruction			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urethral pain			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urethral stenosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary bladder haemorrhage			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary hesitation			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary incontinence			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary retention			
subjects affected / exposed	5 / 101 (4.95%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
Urinary tract disorder			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract obstruction			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract pain			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urine abnormality			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urogenital haemorrhage			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthritis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Back pain			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bone pain			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dupuytren's contracture			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Exostosis of jaw			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Flank pain			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fracture nonunion			

subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
Hypercreatinaemia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intervertebral disc degeneration				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intervertebral disc disorder				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Jaw disorder				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Joint effusion				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lumbar spinal stenosis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Muscular weakness				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Musculoskeletal chest pain				

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Musculoskeletal pain				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myalgia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neck pain				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteitis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteoarthritis				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Osteonecrosis of jaw				
subjects affected / exposed	5 / 101 (4.95%)			
occurrences causally related to treatment / all	5 / 5			
deaths causally related to treatment / all	0 / 0			
Pain in extremity				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Rhabdomyolysis				

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rheumatoid arthritis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rotator cuff syndrome			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal osteoarthritis			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Weight bearing difficulty			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Abscess			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abscess jaw			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abscess of salivary gland			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute sinusitis			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal infection			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Appendicitis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthritis bacterial			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Arthritis infective			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacteraemia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchitis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchopneumonia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac infection			

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
subjects affected / exposed	2 / 101 (1.98%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Chest wall abscess			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chronic sinusitis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Clostridium bacteraemia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Clostridium colitis			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cystitis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dental fistula			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device related infection			

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Device related sepsis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis				
subjects affected / exposed	2 / 101 (1.98%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Empyema				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endocarditis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Enterococcal infection				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Epiglottitis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gangrene				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				

subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal infection				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gingival abscess				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Herpes zoster				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Human ehrlichiosis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infected skin ulcer				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Liver abscess				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lobar pneumonia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Localised infection				

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung infection				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neutropenic infection				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oral candidiasis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Orchitis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteomyelitis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteomyelitis acute				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteomyelitis chronic				

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Penile infection			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Perineal abscess			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Perineal infection			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia pneumococcal			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pseudomonal sepsis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary tuberculosis			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal abscess				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Scrotal abscess				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Septic shock				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sialoadenitis				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tooth infection				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Upper respiratory tract infection				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection				

subjects affected / exposed	3 / 101 (2.97%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection bacterial			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	2 / 101 (1.98%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Viral infection			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound infection			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Decreased appetite			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dehydration			
subjects affected / exposed	3 / 101 (2.97%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Diabetes mellitus			

subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diabetes mellitus inadequate control				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Electrolyte imbalance				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gout				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hyperkalaemia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypocalcaemia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypoglycaemia				
subjects affected / exposed	1 / 101 (0.99%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hypokalaemia				
subjects affected / exposed	0 / 101 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypovolaemia				

subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Iron deficiency			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malnutrition			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 101 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	DB: Placebo	DB: Denosumab	OLE: Placebo/ Denosumab
Total subjects affected by non-serious adverse events			
subjects affected / exposed	585 / 705 (82.98%)	599 / 720 (83.19%)	80 / 109 (73.39%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Metastases to bone			
subjects affected / exposed	58 / 705 (8.23%)	56 / 720 (7.78%)	0 / 109 (0.00%)
occurrences (all)	58	64	0
Vascular disorders			
Hot flush			
subjects affected / exposed	32 / 705 (4.54%)	41 / 720 (5.69%)	1 / 109 (0.92%)
occurrences (all)	36	48	2
Hypertension			
subjects affected / exposed	49 / 705 (6.95%)	59 / 720 (8.19%)	5 / 109 (4.59%)
occurrences (all)	54	74	6
General disorders and administration site conditions			

Asthenia			
subjects affected / exposed	91 / 705 (12.91%)	92 / 720 (12.78%)	8 / 109 (7.34%)
occurrences (all)	145	157	9
Fatigue			
subjects affected / exposed	82 / 705 (11.63%)	98 / 720 (13.61%)	5 / 109 (4.59%)
occurrences (all)	109	153	8
Oedema peripheral			
subjects affected / exposed	88 / 705 (12.48%)	94 / 720 (13.06%)	5 / 109 (4.59%)
occurrences (all)	116	129	8
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	60 / 705 (8.51%)	55 / 720 (7.64%)	6 / 109 (5.50%)
occurrences (all)	87	69	8
Dyspnoea			
subjects affected / exposed	57 / 705 (8.09%)	61 / 720 (8.47%)	4 / 109 (3.67%)
occurrences (all)	68	78	5
Psychiatric disorders			
Insomnia			
subjects affected / exposed	44 / 705 (6.24%)	46 / 720 (6.39%)	4 / 109 (3.67%)
occurrences (all)	49	51	5
Investigations			
Weight decreased			
subjects affected / exposed	42 / 705 (5.96%)	39 / 720 (5.42%)	4 / 109 (3.67%)
occurrences (all)	47	41	5
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	42 / 705 (5.96%)	36 / 720 (5.00%)	3 / 109 (2.75%)
occurrences (all)	51	50	5
Nervous system disorders			
Dizziness			
subjects affected / exposed	56 / 705 (7.94%)	63 / 720 (8.75%)	7 / 109 (6.42%)
occurrences (all)	66	83	9
Headache			
subjects affected / exposed	54 / 705 (7.66%)	67 / 720 (9.31%)	3 / 109 (2.75%)
occurrences (all)	62	91	6
Blood and lymphatic system disorders			

Anaemia subjects affected / exposed occurrences (all)	74 / 705 (10.50%) 110	80 / 720 (11.11%) 122	12 / 109 (11.01%) 15
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	47 / 705 (6.67%) 59	59 / 720 (8.19%) 75	3 / 109 (2.75%) 4
Constipation subjects affected / exposed occurrences (all)	124 / 705 (17.59%) 154	128 / 720 (17.78%) 164	13 / 109 (11.93%) 19
Dental caries subjects affected / exposed occurrences (all)	10 / 705 (1.42%) 12	16 / 720 (2.22%) 17	3 / 109 (2.75%) 3
Diarrhoea subjects affected / exposed occurrences (all)	102 / 705 (14.47%) 141	110 / 720 (15.28%) 195	8 / 109 (7.34%) 11
Nausea subjects affected / exposed occurrences (all)	95 / 705 (13.48%) 120	98 / 720 (13.61%) 152	4 / 109 (3.67%) 4
Toothache subjects affected / exposed occurrences (all)	16 / 705 (2.27%) 20	32 / 720 (4.44%) 41	1 / 109 (0.92%) 1
Vomiting subjects affected / exposed occurrences (all)	55 / 705 (7.80%) 63	59 / 720 (8.19%) 81	3 / 109 (2.75%) 3
Skin and subcutaneous tissue disorders			
Rash subjects affected / exposed occurrences (all)	32 / 705 (4.54%) 42	37 / 720 (5.14%) 48	2 / 109 (1.83%) 2
Renal and urinary disorders			
Dysuria subjects affected / exposed occurrences (all)	66 / 705 (9.36%) 85	73 / 720 (10.14%) 95	5 / 109 (4.59%) 8
Haematuria subjects affected / exposed occurrences (all)	90 / 705 (12.77%) 128	87 / 720 (12.08%) 128	17 / 109 (15.60%) 33
Nocturia			

subjects affected / exposed occurrences (all)	26 / 705 (3.69%) 34	39 / 720 (5.42%) 45	3 / 109 (2.75%) 3
Pollakiuria subjects affected / exposed occurrences (all)	50 / 705 (7.09%) 57	61 / 720 (8.47%) 84	1 / 109 (0.92%) 1
Urinary incontinence subjects affected / exposed occurrences (all)	30 / 705 (4.26%) 34	30 / 720 (4.17%) 35	8 / 109 (7.34%) 9
Urinary retention subjects affected / exposed occurrences (all)	63 / 705 (8.94%) 87	73 / 720 (10.14%) 84	6 / 109 (5.50%) 9
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	116 / 705 (16.45%) 174	123 / 720 (17.08%) 192	11 / 109 (10.09%) 15
Back pain subjects affected / exposed occurrences (all)	159 / 705 (22.55%) 232	166 / 720 (23.06%) 280	24 / 109 (22.02%) 31
Muscle spasms subjects affected / exposed occurrences (all)	28 / 705 (3.97%) 35	46 / 720 (6.39%) 69	6 / 109 (5.50%) 7
Musculoskeletal pain subjects affected / exposed occurrences (all)	59 / 705 (8.37%) 68	58 / 720 (8.06%) 86	8 / 109 (7.34%) 10
Osteoarthritis subjects affected / exposed occurrences (all)	24 / 705 (3.40%) 29	24 / 720 (3.33%) 27	6 / 109 (5.50%) 7
Osteonecrosis of jaw subjects affected / exposed occurrences (all)	0 / 705 (0.00%) 0	17 / 720 (2.36%) 20	1 / 109 (0.92%) 2
Pain in extremity subjects affected / exposed occurrences (all)	88 / 705 (12.48%) 124	101 / 720 (14.03%) 136	12 / 109 (11.01%) 17
Pain in jaw			

subjects affected / exposed occurrences (all)	7 / 705 (0.99%) 9	25 / 720 (3.47%) 29	2 / 109 (1.83%) 2
Infections and infestations			
Bronchitis			
subjects affected / exposed	32 / 705 (4.54%)	40 / 720 (5.56%)	3 / 109 (2.75%)
occurrences (all)	42	48	3
Influenza			
subjects affected / exposed	38 / 705 (5.39%)	49 / 720 (6.81%)	7 / 109 (6.42%)
occurrences (all)	46	65	10
Nasopharyngitis			
subjects affected / exposed	72 / 705 (10.21%)	68 / 720 (9.44%)	7 / 109 (6.42%)
occurrences (all)	90	100	9
Upper respiratory tract infection			
subjects affected / exposed	23 / 705 (3.26%)	46 / 720 (6.39%)	8 / 109 (7.34%)
occurrences (all)	25	59	10
Urinary tract infection			
subjects affected / exposed	96 / 705 (13.62%)	108 / 720 (15.00%)	15 / 109 (13.76%)
occurrences (all)	159	187	28
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	61 / 705 (8.65%)	63 / 720 (8.75%)	7 / 109 (6.42%)
occurrences (all)	70	95	9

Non-serious adverse events	OLE: Denosumab/ Denosumab		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	74 / 101 (73.27%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Metastases to bone			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences (all)	1		
Vascular disorders			
Hot flush			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences (all)	1		
Hypertension			

subjects affected / exposed occurrences (all)	6 / 101 (5.94%) 11		
General disorders and administration site conditions Asthenia subjects affected / exposed occurrences (all) Fatigue subjects affected / exposed occurrences (all) Oedema peripheral subjects affected / exposed occurrences (all)	11 / 101 (10.89%) 17 8 / 101 (7.92%) 13 11 / 101 (10.89%) 17		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Dyspnoea subjects affected / exposed occurrences (all)	4 / 101 (3.96%) 5 4 / 101 (3.96%) 10		
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	2 / 101 (1.98%) 2		
Investigations Weight decreased subjects affected / exposed occurrences (all)	6 / 101 (5.94%) 6		
Injury, poisoning and procedural complications Fall subjects affected / exposed occurrences (all)	3 / 101 (2.97%) 3		
Nervous system disorders Dizziness subjects affected / exposed occurrences (all) Headache	6 / 101 (5.94%) 7		

subjects affected / exposed occurrences (all)	5 / 101 (4.95%) 9		
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	10 / 101 (9.90%) 17		
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all) Constipation subjects affected / exposed occurrences (all) Dental caries subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Toothache subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all)	7 / 101 (6.93%) 10 15 / 101 (14.85%) 19 6 / 101 (5.94%) 9 10 / 101 (9.90%) 17 14 / 101 (13.86%) 18 6 / 101 (5.94%) 12 10 / 101 (9.90%) 15		
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	3 / 101 (2.97%) 3		
Renal and urinary disorders Dysuria subjects affected / exposed occurrences (all) Haematuria	7 / 101 (6.93%) 8		

subjects affected / exposed	11 / 101 (10.89%)		
occurrences (all)	19		
Nocturia			
subjects affected / exposed	3 / 101 (2.97%)		
occurrences (all)	3		
Pollakiuria			
subjects affected / exposed	2 / 101 (1.98%)		
occurrences (all)	2		
Urinary incontinence			
subjects affected / exposed	4 / 101 (3.96%)		
occurrences (all)	4		
Urinary retention			
subjects affected / exposed	7 / 101 (6.93%)		
occurrences (all)	7		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	9 / 101 (8.91%)		
occurrences (all)	12		
Back pain			
subjects affected / exposed	8 / 101 (7.92%)		
occurrences (all)	9		
Muscle spasms			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences (all)	1		
Musculoskeletal pain			
subjects affected / exposed	5 / 101 (4.95%)		
occurrences (all)	8		
Osteoarthritis			
subjects affected / exposed	1 / 101 (0.99%)		
occurrences (all)	1		
Osteonecrosis of jaw			
subjects affected / exposed	12 / 101 (11.88%)		
occurrences (all)	13		
Pain in extremity			

subjects affected / exposed	10 / 101 (9.90%)		
occurrences (all)	11		
Pain in jaw			
subjects affected / exposed	6 / 101 (5.94%)		
occurrences (all)	9		
Infections and infestations			
Bronchitis			
subjects affected / exposed	3 / 101 (2.97%)		
occurrences (all)	4		
Influenza			
subjects affected / exposed	6 / 101 (5.94%)		
occurrences (all)	6		
Nasopharyngitis			
subjects affected / exposed	4 / 101 (3.96%)		
occurrences (all)	5		
Upper respiratory tract infection			
subjects affected / exposed	8 / 101 (7.92%)		
occurrences (all)	8		
Urinary tract infection			
subjects affected / exposed	14 / 101 (13.86%)		
occurrences (all)	28		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	5 / 101 (4.95%)		
occurrences (all)	5		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 June 2007	<p>The screening visit window was increased to \leq weeks to allow greater flexibility in scheduling the screening procedures.</p> <p>The requirement for an end-of-study bone scan was removed if bone metastasis had been confirmed by the central imaging vendor.</p> <p>The radiology component of the study was clarified: at baseline, full body radioisotope bone scans were required for the exclusion of bone metastasis and on-study full body radioisotope bone scans were required for the detection of bone metastasis.</p>
30 October 2009	<p>The double-blind treatment phase was extended to allow subjects to receive investigational product until the benefit:risk profile for denosumab compared with placebo was determined based on the primary analysis results. An open-label extension phase was added, with enrollment dependent on the benefit:risk profile. Specifically, if denosumab's benefit:risk profile was positive, subjects currently undergoing Q4W scheduled assessments were to be given the option to receive open-label denosumab 120 mg Q4W until subjects develop a bone metastasis, for up to 3 years, or until denosumab is commercially available, whichever comes first. If the benefit:risk profile was not positive, subjects were to complete an end-of-study visit within 4 weeks of the last dose of blinded investigational product and be followed for survival for a period of 3 years.</p> <p>For countries that required a separate protocol for the open-label extension phase and, thus, did not accept protocol amendment 2 (ie, United Kingdom and Czech Republic), the protocol was amended to extend the double-blind treatment phase only (ie, to allow subjects to receive investigational product until the benefit:risk profile for denosumab was determined based upon the primary analysis results). For these countries, the open-label extension will be conducted under protocol number 20080585.</p> <p>The planned statistical analyses were revised to reflect the extended double-blind treatment phase and open-label treatment phase and other changes to the statistical analysis plan.</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported